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Abstract
Background The development of molecularly tailored therapeutic agents such as the BCR/ABL-active tyrosine kinase 
inhibitors (TKi) resulted in an excellent treatment option for chronic myeloid leukemia (CML) patients. However, following 
TKi discontinuation, disease relapses in 40–60% of patients, an occurrence very likely due to the persistence of leukemic 
stem cells that are scarcely sensitive to TKi. Nevertheless, TKi are still the only current treatment option for CML patients.
Objective The aim of this study was to compare the effects of TKi belonging to different generations, imatinib and ponatinib 
(first and third generation, respectively), on progenitor/stem cell expansion potential and markers.
Patients and Methods We used stabilized CML cell lines (KCL22, K562 and LAMA-84 cells), taking advantage of the 
previous demonstration of ours that cell lines contain cell subsets endowed with progenitor/stem cell properties. Primary 
cells explanted from CML patients were also used. The effects of TKi on the expression of stem cell related genes were 
compared by quantitative PCR. Flow cytometry was performed to evaluate aldehyde-dehydrogenase (ALDH) activity and 
the expression of cluster of differentiation (CD) cell surface hematopoietic stem cell markers. Progenitor/stem-cell potential 
was estimated by serial colony formation ability (CFA) assay.
Results Ponatinib was more effective than imatinib for the reduction of cells with ALDH activity and progenitor/stem-cell 
potential of CML patient-derived cells and cell lines. Furthermore, ponatinib was more effective than imatinib in reducing 
the percentage of CD26-expressing cells in primary CML cells, whereas imatinib and ponatinib showed similar efficacy on 
KCL22 cells. Both drugs strongly upregulated NANOG and SOX2 in CML cell lines, but in KCL22 cells this upregulation 
was significantly lower with ponatinib than with imatinib, an outcome compatible with a lower level of enrichment of the 
stem-cell compartment upon ponatinib treatment.
Conclusion Ponatinib seems to target CML progenitor/stem cells better than imatinib.
1 Introduction
The pathogenesis of chronic myeloid leukemia (CML) is 
centered on the expression of the BCR/ABL oncoprotein, a 
constitutively active tyrosine kinase [1]. The clinical course 
of untreated CML typically includes an initial chronic phase 
(CP) lasting 3–5 years, an accelerated phase (AP) lasting 
6–18 months, and a final, short, blast crisis (BC) with poor 
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prognosis. The introduction of imatinib-mesylate, the proto-
typical tyrosine kinase inhibitor (TKi) active on BCR/ABL, 
signaled a new era in the treatment of CML, allowing up 
to 90% of CP-CML patients to survive after 20 years of 
treatment [2]. However, imatinib and subsequent second- 
(dasatinib, bosutinib, and nilotinib) and third- (ponatinib) 
generation TKi are not very effective in preventing the 
relapse of disease, as shown in particular by the outcome 
of TKi discontinuation protocols in CP patients. Several 
studies showed indeed that 40–60% of even well respond-
ing (sustained deep molecular remission) patients who have 
stopped therapy undergo relapse of disease (in 80% of cases, 
within the first 6 months) and require the restart of treat-
ment, while others maintain treatment-free remission, in 
some cases despite the persistence of detectable molecu-
lar disease [3–7]. Based on available data, it is likely that 
relapse after TKi discontinuation is due to the persistence of 
leukemic stem cells (LSC), which apparently are relatively 
resistant to TKi [8–11]. However, while the identification of 
new treatments capable of targeting CML progenitor/stem 
cells seems necessary when aiming for eradication of disease 
[12, 13], TKi are still the only current treatment option for 
CML patients.
In CML, LSC are located within the CD34 +/CD38 − cell 
fraction, a phenotype which is, however, not exclusive to 
LSC of CML [14]. Therefore, different markers have been 
tested for being capable to discriminate LSC of CML from 
normal hematopoietic stem cells (HSC). Along this line, 
CD26 (dipeptidyl-peptidase IV) has been identified as a 
potential marker for the quantification and isolation of 
LSC in bone marrow (BM) samples of CML patients [15]. 
Indeed, while other antigens such as CD90 and IL-1RAP are 
co-expressed by LSC of CML and acute myeloid leukemia 
as well as by HSC, CD26 is consistently expressed in CP-
CML patients, but it is not in HSC or stem cells of other 
myeloid neoplasms [15, 16]. Importantly, the concentration 
of CD26 + LSC correlates with resistance to TKi and identi-
fies TKi-resistant sub-clones [17].
Stem cells from a variety of tissues exhibit high levels of 
aldehyde dehydrogenase (ALDH) activity, which is therefore 
considered a stem-cell feature [18, 19]. HSC in particular 
are characterized by high ALDH activity [20–22], and cells 
with high ALDH activity and low side scattering are self-
renewing and multipotent [21]. Based on all of the above, 
high ALDH activity has been increasingly used as a selecta-
ble marker for cell populations enriched in tumor-initiating 
stem-like cells in multiple types of cancers, including leu-
kemias [23, 24].
Another set of potentially useful stem cell markers is rep-
resented by those defining the self-renewal and pluripotency 
of embryonic stem cells (ESC), including the transcription 
factors OCT4, SOX2, and NANOG [25–28]. The expression 
of OCT4 is indeed considered restricted to pluripotent stem 
cells, its expression being down-regulated in the course of 
differentiation, to reach undetectability in adult normal tis-
sues [29]. SOX2, another transcriptional regulator of pluri-
potency and self-renewal in ESC [30, 31], has also been 
found expressed in a number of tumors [32–34]. Like OCT4 
and SOX2, NANOG has been reported to be expressed in 
many tumors, and its knockdown to inhibit tumor devel-
opment [35]. This set of markers also includes c-MYC, a 
proto-oncogene important for the regulation of the stem cell 
compartment [36, 37].
In this study, we compared the effects of TKi belonging to 
different generations, imatinib and ponatinib, on the expres-
sion of progenitor/stem-cell markers and potential in both 
CML cell lines, taking advantage of our previous demonstra-
tion that leukemic cell lines contain cell subsets endowed 
with progenitor/stem-cell properties [9, 12, 13, 38, 39], as 
well as patient-derived cells.
2  Methods
2.1  Cells and Culture Conditions
K562 [40] and KCL22 [41] (kindly supplied by Dr A.M. 
Vannucchi, Azienda Ospedaliero/Universitaria Careggi, 
Florence, Italy), LAMA-84 [42], and the imatinib-resistant 
LAMA-84R [43, 44] (kindly supplied by Dr C. Gambacorti-
Passerini, University of Milano-Bicocca & San Gerardo 
Hospital, Monza, Italy) blast-crisis CML cells and Kasumi-1 
[45] and NB4 [46] acute myeloid leukemia cells (kindly sup-
plied by Dr C. Chomienne Université Denis Diderot, Paris, 
France) were cultured in RPMI 1640 medium supplemented 
with 10% heat-inactivated fetal bovine serum (FBS), 2 mM 
glutamine, 50 U/mL penicillin, and 50 mg/mL streptomy-
cin (all from EuroClone, Paignton, UK), and incubated at 
37 °C in a water-saturated atmosphere containing 95% air 
(21%  O2) and 5%  CO2. CML cell lines were routinely tested 
for mycoplasma contamination, BCR/ABL expression, and 
annually for their identity (Promega PowerPlex Fusion Sys-
tem kit; BMR Genomics, Padova, Italy). Cell cultures were 
renewed every 3 months by thawing a new vial of frozen 
cells.
Patient-derived CML cells (see Table 1 for patients’ 
characteristics) were collected following informed consent 
and under approval of the Ethical Committee of AOUC 
(authorization no. 520/10, October 18, 2010, renewed with 
no. 2015/0032965, November 4, 2015). Mononuclear cells 
(MCs) from BM of CML patients were isolated by Ficoll-
Hypaque gradient (Cedarlane Laboratories, ON, Canada). 
CML BMMCs were cultured in IMDM supplemented with 
20% FBS, 2 mM glutamine, 50 U/mL penicillin, 50 mg/
mL streptomycin (all from EuroClone, Paignton, UK), and 
50 ng/mL Flt-3 ligand (cat. no. 300-19), 20 ng/mL TPo (cat. 
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no. 300-18), 50 ng/mL stem cell factor (SCF) (cat. no. 300-
07) and 10 ng/mL interleukin-3 (IL-3) (cat. no. 200-03) (all 
from PeproTech, Rocky Hill, NJ, USA).
Experiments were performed with cells harvested from 
maintenance cultures by sub-culturing viable cells (5 × 105/
mL) in fresh medium for 24 h before seeding for the experi-
ments (3 × 105/mL). Cells were counted in a hemocytometer 
and cell viability was assessed by trypan blue exclusion test 
(Table 2).
2.2  IC50 Determination in Cytotoxicity Experiments
Exponentially growing KCL22, LAMA-84, and K562 
cells from routine cultures were seeded in fresh medium 
at 3 × 105 cells/mL. Cells were treated with dimethyl-sul-
foxide (DMSO; vehicle) or increasing doses of TKi at the 
beginning of incubation (treatment at time 0). Half maximal 
inhibitory concentration  (IC50) values were determined by 
counting viable cells following trypan blue staining after 
72 h of treatment and processing data with GraphPad Prism 
software (La Jolla, CA, USA).
2.3  Drugs
Imatinib (cat. no. 202180, Santa Cruz, Biotechnology, Dal-
las, TX, USA) [47], dasatinib (cat. no. HY-10181) [48], 
nilotinib (cat. no. HY-10159) [49], ponatinib (cat. no. 
HY-12047) [50], bosutinib (cat. no. HY-10158) [51], and 
XMD8-92 (cat. no. HY-14443) [52, 53], from MedChem-
Express (LLC, Princeton, NJ, USA), were all dissolved in 
DMSO.
2.4  Immunophenotype Determination
To analyze cell surface markers,  105 cells were stained 
with anti-human-CD26-PE (#12-0269), -CD90(Thy-1)-PE-
Cyanine7 (#25-0909) from Affymetrix eBioscience (San 
Diego, CA, USA) [13], or with anti-human CD38-APC 
(#21270386), -CD34-FITC (#21270343) from Immuno-
Tools, JPT Peptide Technologies GmbH (Berlin, Germany) 
for 30 min at 4 °C in the dark. Expression of cell surface 
markers was measured with a FACSCanto flow-cytometer 
(Becton–Dickinson, Franklin Lakes, NJ, USA). Background 
signal was established in the same populations by staining 
with matched isotype control.
2.5  ALDH Activity Measurement
ALDH enzymatic activity was quantified by flow cytometry 
using the Aldefluor kit (#01700, Stem Cell Technologies, 
Vancouver, BC, Canada) [54] according to the manufac-
turer’s instructions. Non-viable cells were excluded from 
analysis following staining with 7-actino-aminomycin-D 
(7-AAD; BD Biosciences, San Jose, CA, USA). Diethyl-
aminobenzaldehyde (DEAB), a specific inhibitor of ALDH, 
was used to determine background fluorescence.
Table 1  Patients’ characteristics
CML chronic myeloid leukemia, ECP early chronic phase, ELN European Leukemia Net (2013)
Patient ID Age at diag-
nosis
CML phase Sokal risk BCR/ABL transcript ELN criteria response
23 42 ECP Intermediate b3a2 (p210) e1a2 (p190) Optimal response to nilotinib
33 59 ECP Intermediate b3a2 (p210) Optimal response to nilotinib
46 75 ECP Low b3a2 (p210) Optimal response to imatinib
47 65 ECP High b3a2 (p210) Optimal response to dasatinib
Table 2  Characteristics of CML cell lines used in the text
CML chronic myeloid leukemia, BC blast crisis; ++ high expression, ± low expression, − no expression
Cell line Cell type BCR-ABL junction type Derivation ALDH activity CD34 CD38 CD26 CD90
K562 BC CML e14-a2 (b3-a2) Pleural effusion of a 53-year-old woman with 
CML in terminal BC [40]
++ − +/− − −
LAMA-84 BC CML e14-a2 (b3-a2) Peripheral blood of a 29-year-old woman with 
CML after onset of myeloid-megakaryocytic 
BC [42]
++ − +/− − −
KCL22 BC CML e13-a2 (b2-a2) Pleural effusion of a 32-year-old woman with 
CML [41]
± − +/− ++ −
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2.6  RNA Extraction and Quantitative PCR
Total RNA was extracted using Trizol reagent (Thermo 
Fisher Scientific) following the manufacturer’s protocol. 
Residual DNA was removed by Deoxyribonuclease I (Roche 
Diagnostics, Lewes, UK). The quality of extracted RNA was 
evaluated in a 2% agarose gel. RNA 2 µg were retro-tran-
scribed into cDNA using the ImProm-IITM Reverse Tran-
scription System kit (Promega, Madison, WI, USA) follow-
ing the manufacturer’s instructions. Quantitative polymerase 
chain reaction (q-PCR) was performed as described previ-
ously [55] and carried out using Green GoTaq q-PCR Mas-
ter Mix (Promega). Primers (Qiagen, Hilden, Germany) for 
c-MYC, NANOG, SOX2, OCT4, KLF4, β-actin, and GAPDH 
are described in Supplementary Table S1 (see electronic 
supplementary material [ESM]).
2.7  Colony Formation Ability (CFA) Assay
K562 (300 cells/dish) and KCL22 (750 cells/dish) cells as 
well as CML BMMCs (10,000 cells/dish) were suspended in 
IMDM containing 2% FBS, 100 U/mL penicillin/streptomy-
cin. Cells were plated in methylcellulose-containing medium 
(StemCell Technologies #04230 for CML cell lines, #04435 
for CML BMMCs) in 35-mm dishes and treated with drugs 
from time 0 to the end of primary culture (day 7). Cells 
recovered from day-7 cultures were washed to remove drugs 
and replated weekly (passages II–III) in methylcellulose-
containing medium. Colonies were scored on day 7 after 
each passage.
2.8  Statistical Analysis
Data represent means ± standard error of the mean (SEM) 
or means ± standard deviation (SD) of values obtained from 
at least three independent experiments. The exact number 
of experiments performed and used for statistical analysis 
is indicated in each figure legend. Variance between groups 
that were statistically compared was similar. p Values were 
calculated using Student’s t test (two groups) or one-way 
analysis of variance (more than two groups; multiple com-
parison using Bonferroni’s correction). A two-tailed value 
of p < 0.05 was considered statistically significant.
3  Results
3.1  Effects of Imatinib and Ponatinib on Stem‑Cell 
Markers in CML Cells
We determined first the  IC50 values relative to the effects 
of several TKi on viable cell number in cultures of three 
CML cells lines (Fig. 1). Imatinib showed the highest  IC50 
value, and the  IC50 of ponatinib and dasatinib were lower 
than those of nilotinib and bosutinib. Thus, the data show 
a good progression of efficacy going from first to second to 
third TKi generation. The  IC50 values were similar in all cell 
lines, suggesting that the use of a panel of CML cell lines to 
assess the overall effects of TKi is adequate. Based on these 
results and on the fact that ponatinib is a third-generation 
TKi, we chose to compare the effects of imatinib with those 
of ponatinib on a number of progenitor/stem-cell features.
CML stem cells, besides being CD34 +/CD38 −/CD90 + , 
express CD26, a CML-specific stem-cell marker [15, 
56–58]. With the aim of comparing the effects of ponatinib 
with those of imatinib on CML progenitor/stem cells, we 
performed a characterization of the above cell surface mol-
ecules in a number of CML cell lines (Figs. 2, 3a; Table 2). 
All three CML cell lines tested were CD34-negative, a fea-
ture previously reported for K562 cells [40, 59], and shown 
to include a small subpopulation of CD38 + cells (Fig. 2), 
at variance with previous data showing that K562 cells do 
not express CD38 [59]. The acute myeloid leukemia cell 
lines Kasumi-1 and NB4 were used as positive controls for 
the expression of CD34 or CD38, respectively [59–61]. All 
three CML cell lines were found to be negative for CD90 
(Fig. 3a). CD26 was expressed at high levels in KCL22, but 
not in K562 and LAMA-84 cells, as previously reported by 
us and others [13, 62] (Fig. 3a). The pattern of CD expres-
sion in LAMA-84R (imatinib-resistant) cells was identi-
cal to that of LAMA-84 cells (not shown). Based on all of 
the above, CD26 emerged as the only cell surface marker 
suitable to monitor progenitor/stem cells for subsequent 
experiments. Using imatinib and ponatinib at around two-
fold the  IC50 concentrations, we found that the two drugs 
are similarly effective in reducing the percentage of CD26-
expressing cells (Fig. 3b). The same results were obtained 
when analyzing mean fluorescence intensity (MFI) values 
(Supplementary Fig. S1a, see ESM). Importantly, when 
the effects of the two drugs were tested on primary cells 
explanted from CML patients, we found that ponatinib was 
significantly more effective than imatinib in reducing the 
percentage of CD26 +/CD34 + cells (Fig. 3c, Supplementary 
Fig. S1b [see ESM]). XMD8-92, a small-molecule inhibitor 
of ERK5 that we previously showed to suppress progenitor/
stem cell potential of primary CML cells [13], was used as 
a positive control.
We then tested the effects of imatinib and ponatinib on 
cells endowed with ALDH activity using K562, LAMA-84, 
and LAMA-84R cells that, differently from KCL22 cells, 
show high levels of ALDH activity (Supplementary Fig S2a 
[see ESM]; Table 2), in agreement with data reported previ-
ously for K562 cells [63, 64]. Both drugs similarly reduced 
the percentages (Fig. 4a, b) and MFI values (Supplementary 
Fig. S2b [see ESM]) of ALDH-expressing cells in K562 
cells, while ponatinib was significantly more effective than 
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Fig. 1  TKi  IC50 determination in CML cell lines. KCL22, LAMA-84, 
and K562 cells (3 × 105/mL) were cultured for 72 h in RPMI medium 
supplemented with 10% FBS in the presence of the indicated drugs or 
their solvent DMSO. Viable cells were counted by trypan-blue exclu-
sion and  IC50 were calculated by the GraphPad software.  IC50 values 
are indicated in the Table. Graphs show TKi dose/response curves 
after 72 h of treatment or vehicle. Values are mean ± SD of data from 
three independent experiments normalized to matched vehicle-treated 
sample. CML chronic myeloid leukemia, DMSO dimethyl-sulfoxide, 
FBS fetal bovine serum, IC50 half maximal inhibitory concentration, 
TKi tyrosine kinase inhibitors
Fig. 2  Evaluation of the expression of the CD34 and CD38 cell sur-
face markers in CML cell lines. The expression of CD34 and CD38 
in routinely cultured cells was assessed by flow cytometry. Dot plots 
from one representative experiment are shown. The background sig-
nal was measured by cell staining with matched-isotype IgG controls. 
Values represent mean ± SD of data from three independent experi-
ments. Kasumi-1 and NB4 cells were used as positive controls for 
CD34 and CD38, respectively
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imatinib in LAMA-84 cells. Neither imatinib nor ponatinib 
was capable of reducing the ALDH activity of LAMA-84R 
cells (Fig. 4b, Supplementary Fig. S2c). The enhanced effi-
cacy of ponatinib with respect to imatinib was confirmed 
on primary CML cells (Fig. 4c, Supplementary Fig. S2d 
[see ESM]).
3.2  Effects of Imatinib and Ponatinib 
on the Expression of Stem Cell–Related Genes 
in CML Cells
Both imatinib and ponatinib markedly reduced the expres-
sion of c-MYC, a proto-oncogene important for the regula-
tion of stem cell compartments [36, 37], in either KCL22 
or K562 cells (Fig. 5a). Moreover, both drugs upregulated 
the expression of the NANOG, SOX2, and OCT4 stem-
cell–related genes [65–67] with respect to control cells (Sup-
plementary Fig. S3a [see ESM]), an effect likely due to the 
scarce sensitivity of LSC to TKi. Interestingly, in KCL22 
cells, the upregulation of NANOG and SOX2 expression 
under ponatinib treatment was significantly lower than that 
induced by imatinib (Fig. 5b). Furthermore, no statistically 
significant difference as for KLF4 expression was found 
between imatinib- and ponatinib-treated cells (Supplemen-
tary Fig. S3a, b [see ESM]). In these experiments, cells were 
exposed to higher concentrations of both drugs (around 
4-fold  IC50) with respect to the experiments of Figs. 3 and 
4, due to the fact that cells were incubated for shorter times.
3.3  Effects of Imatinib and Ponatinib on Progenitor/
Stem Cell Potential of CML Cells
In order to evaluate functionally, rather than pheno-
typically, the effects of imatinib and ponatinib on CML 
progenitor/stem-cell potential, cells were subjected to 
serial CFA assay (Fig. 6) [12, 13]. Both drugs strikingly 
(KCL22, Fig. 6a) or markedly (K562, Fig. 6b) reduced 
CFA in primary semisolid cultures (passage I), an effect 
which was progressively quenched as cells were replated 
to secondary and tertiary cultures (passages II–III). 
XMD8-92, used as a positive control for its suppressive 
effect on CML progenitor/stem-cell potential (see above 
and [13]), maintained or even enhanced the inhibitory 
effect on CFA throughout the subsequent replatings. Of 
note, ponatinib did progressively better than imatinib 
along the subsequent passages, an outcome compatible 
Fig. 3  Effects of TKi on CD26-expressing CML cells. a The expres-
sion of CD90 and CD26 cell surface antigens in routinely cultured 
cells was assessed by flow cytometry using specific antibodies (Ab). 
Cell mean fluorescence intensity (MFI), calculated using matched-
isotype IgG as negative control (control IgG), and the percentages 
of CD26-expressing cells obtained from the same experiments are 
reported in the table. Values represent mean ± SD of data obtained 
from three independent experiments. b KCL22 cells (3 × 105/mL) 
were treated with DMSO (vehicle), 1 μM imatinib or 4 nM ponatinib 
at time 0 and incubated for 72 h. Histograms relative to the average 
percentages of KCL22 cells expressing CD26 from three independ-
ent experiments (mean ± SD) are shown. *p < 0.05, **p < 0.01; ns not 
significant. c Patient-derived CML cells (3 × 105/mL) were treated 
with DMSO (vehicle), 1  μM imatinib, 4  nM ponatinib or 10  μM 
XMD8-92 at time 0 and incubated for 72  h. Histograms relative to 
the average percentages of CD26/CD34-expressing cells from three 
patients (mean ± SD) are shown. See Supplementary Fig. S1b for 
single patient data in the electronic supplementary material. CML 
chronic myeloid leukemia, DMSO dimethyl-sulfoxide, TKi tyrosine 
kinase inhibitors; *p < 0.05, **p < 0.01, ***p < 0.001
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with an enhanced effect of ponatinib on progenitors of 
relatively higher hierarchical level. Differences between 
imatinib and ponatinib were significant for KCL22 
cells from passage III and for K562 cells from passage 
I. Ponatinib, differently from imatinib, maintained an 
inhibitory effect on CFA until passage III for K562 cells. 
Serial CFA assays performed with primary CML cells 
yielded results similar to those obtained for CML cell 
lines (Fig. 6c, Supplementary Fig. S4 [see ESM]). Indeed, 
both drugs markedly reduced CFA from passage I, the 
effect being progressively quenched along subsequent 
passages. However, at passage III, ponatinib was more 
effective than imatinib (Fig. 6c). Again, XMD8-92 was 
used as a positive control [13].
In order to evaluate the correspondence between func-
tional and phenotypical features of CML stem/progenitor 
cells in relation to their sensitivity to treatment, the effects 
of TKi on CD26 expression or ALDH activity were evalu-
ated at each passage of serial CFA assays (Fig. 6d). Both 
drugs markedly reduced the percentage of CD26-express-
ing KCL22 cells at passage I, but this effect was no longer 
detected from passage II onward (Fig. 6d, left). It is useful 
to point out that control vehicle-treated KCL22 cultures con-
tained fewer CD26 + cells at the end of passage I (around 
45%) than at time 0 (Fig. 3a, table), a fact possibly due to 
Fig. 4  Effects of TKi on CML cells endowed with ALDH activity. 
a K562 and LAMA-84 cells (3 × 105/mL) were treated with DMSO 
(vehicle), 1  μM imatinib or 4  nM ponatinib at time 0 and incu-
bated for 72 h. The enzymatic activity of ALDH in viable cells was 
assessed by flow cytometry. The gating for ALDH activity-negative 
cells (control) was performed in the presence of the ALDH inhibi-
tor DEAB (upper plots). Percentages of ALDH activity-positive 
viable cells averages (± SD) from three independent experiments are 
show in representative plots. b Data from a are plotted in the graphs 
together with statistical analysis; *p < 0.05, **p < 0.01; ns not sig-
nificant. Data obtained from similar experiments carried out with 
LAMA-84R are also shown. See Supplementary Fig. S2c for rep-
resentative dot plots from one out of three experiments performed 
with LAMA-84R (electronic supplementary material). c Patient-
derived CML cells (3 × 105/mL) were treated with DMSO (vehicle), 
1 μM imatinib, 4 nM ponatinib, or 10 μM XMD8-92 at time 0 and 
incubated for 72 h. The percentages of ALDH activity-positive via-
ble cells from three patients (mean ± SD) were determined by flow 
cytometry. *p < 0.05, **p < 0.01, ***p < 0.001. Data obtained for 
individual patients are shown in Supplementary Fig. S2d (see elec-
tronic supplementary material). ALDH aldehyde-dehydrogenase, 
CML chronic myeloid leukemia, DMSO dimethyl-sulfoxide, TKi 
tyrosine kinase inhibitors
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the suppression in the course of culture of a sizeable subset 
of CD26 + cells of relatively low hierarchical level. Like-
wise, a significant reduction of the percentage of K562 cells 
expressing ALDH activity under ponatinib treatment was 
observed at passage I only, while imatinib did not show any 
effect at any passage (Fig. 6d, right). Taken together, these 
Fig. 5  Effects of TKi on the expression of stem-cell–related genes in 
CML cell lines. Cells (3 × 105/mL) were treated with DMSO (CON), 
2 μM imatinib (IM) or 8 nM ponatinib (PON) at time 0 and incubated 
for 24 h and c-MYC (a), NANOG, SOX2, and OCT4 (b) mRNA were 
measured by Q-PCR. Data were normalized with respect to the mean 
of GAPDH and β-actin mRNA levels and expressed as fold-change 
with respect to the values obtained for CON samples. Values repre-
sent mean ± SEM of three independent experiments, each carried out 
in triplicate. *p < 0.05; CML chronic myeloid leukemia, DMSO dime-
thyl-sulfoxide, GAPDH glyceraldehyde 3-phosphate dehydrogenase, 
Q-PCR quantitative polymerase chain reaction, SEM standard error of 
the mean, TKi tyrosine kinase inhibitors
Fig. 6  Effects of TKi on serial CFA of CML cells. Cells were incu-
bated in semisolid medium and treated with DMSO (vehicle), 1 μM 
imatinib, 4 nM ponatinib or 10 μM XMD8-92 from time 0 to the end 
of primary culture (day 7; passage I). Colony cells were rescued and 
washed to remove drugs and replated (passage II); colony cells from 
drug-free, day-7 passage II cultures were then replated and incu-
bated for 7 further days (passage III). Colonies were scored on day 
7 after each passage. a, b Values are mean ± SD of data from three 
independent experiments each performed in duplicate. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001. c Values are mean ± SD 
of data, normalized for vehicle-treated control, from three patients, 
each CFA assay being performed in duplicate. *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001. Data obtained for individual patients 
are shown in Supplementary Fig. S4 (see electronic supplementary 
material). d Expression of CD26 or ALDH activity, respectively, 
in KCL22 (left) or K562 (right) viable cells rescued from each pas-
sage of serial CFA assays shown in a and b. The percentages of cells 
expressing CD26 or ALDH activity as determined by flow cytom-
etry from three independent experiments (mean ± SD) are shown. 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ALDH alde-
hyde-dehydrogenase, CFA colony formation ability, CML chronic 
myeloid leukemia, DMSO dimethyl-sulfoxide, TKi tyrosine kinase 
inhibitors
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results seem to indicate that an LSC-like phenotype was 
selected progressively in culture across subsequent passages, 
paralleled by a loss of sensitivity to TKi.
4  Discussion
The development of molecularly tailored therapeutic agents 
such as BCR/ABL-active TKi led to the availability of an 
excellent treatment for CML. However, although capable of 
efficiently inducing remission of disease, neither imatinib 
nor later-generation TKi are very effective in preventing 
relapse upon treatment discontinuation. This is due to a 
number of reasons, including a relatively low efficacy of TKi 
on the LSC of CML [11, 68]. Despite the intensive research 
to develop non-TKi-based strategies capable of targeting 
TKi-insensitive LSC, TKi are still the only current treat-
ment option for CML patients. It is to be noted, however, 
that a sizeable percentage of patients do not undergo relapse 
following TKi treatment discontinuation, indicating that in 
some cases TKi are actually effective on the CML stem/pro-
genitor cell compartment(s). This prompted us to evaluate 
the effects of imatinib and ponatinib on a number of stem/
progenitor cell features. In this study, ponatinib was more 
effective than imatinib in reducing cells with ALDH activ-
ity as well as the progenitor/stem-cell potential of CML cell 
lines and patient-derived cells. In the latter, ponatinib did 
better that imatinib in reducing the number of CD26 + cells. 
Furthermore, ponatinib was less effective than imatinib 
in increasing the expression of NANOG and SOX2 stem-
cell–related genes.
When the effects of TKi on cells endowed with ALDH 
activity were tested, ponatinib was more effective than 
imatinib in reducing the percentage of ALDH activity-
positive cells in primary CML cells and LAMA-84 cells. 
Imatinib and ponatinib exhibited comparable efficacy in 
K562 cells. The effect of imatinib on the K562 cell frac-
tion expressing ALDH had been previously reported [69], 
while that of ponatinib on K562 cells and of imatinib or 
ponatinib on LAMA-84 cells have, to our knowledge, never 
been described before. It is worth pointing out that LAMA-
84R cells, selected for resistance to imatinib, were equally 
insensitive to ponatinib as for the maintenance of ALDH-
positive cells in culture (Fig. 4b). This effect was expected, 
as the mechanism of induction of LAMA-84R resistance to 
imatinib relies on BCR/ABL amplification [43]. The ALDH 
experiments seem to indicate, on one hand, that imatinib is 
actually capable of hitting, at least partially, the more imma-
ture fraction of CML cell population, and on the other hand, 
that in this respect the later-generation ponatinib is more 
effective than imatinib.
CD26 is nowadays considered the only CML-specific 
marker of LSC, and may be exploited as a prognostic marker 
of relapse [15]. In our study, ponatinib was more effec-
tive than imatinib in reducing the percentages of CD34 +/
CD26 + primary CML cells, whereas imatinib and ponatinib 
showed similar efficacy in cultures of KCL22 cells. Other 
interesting observations came from the CFA assay per-
formed with KCL22, where the effects of TKi progres-
sively decreased, indicating that the CD26-positive popula-
tion is heterogeneous and composed of TKi-sensitive and 
TKi-insensitive cell subsets. The existence of this duality 
seems to mirror the clinical observation that the percent-
age of CD26 + CML cells is reduced to low or undetectable 
levels in CML patients who respond to imatinib therapy 
and increases in peripheral blood and BM in the course of 
relapse of disease [17]. In this respect, when compared with 
CD26-positive cells, the ALDH-positive cells were overall 
more TKi resistant, indicating that the latter subpopulation 
includes relatively more immature progenitor/stem cells.
The effects of TKi on other phenotypic features were also 
addressed by evaluating the effects of imatinib and ponatinib 
on the expression of stem-cell–related genes, including 
NANOG, SOX2, c-MYC, and KLF4. Either drug strongly 
upregulated NANOG and SOX2 in KCL22 and K562 cells, 
but in KCL22 cells this upregulation was significantly lower 
with ponatinib than with imatinib. The fact that the increase 
of NANOG and SOX2 expression was less pronounced with 
ponatinib than with imatinib cannot be attributed, in our 
opinion, to a reduced effect of ponatinib on stem-cell pool, 
rather to the possibility that ponatinib, while determin-
ing, like imatinib, an enrichment of less immature cells, 
is in addition better suited than imatinib to suppress the 
NANOG +/SOX2 + cell subset. While the increased expres-
sion of NANOG and SOX2 by imatinib has been previously 
reported [70, 71], the effects of ponatinib shown here are 
novel. Both drugs, on the contrary, markedly reduced the 
expression of c-MYC. This is in agreement with the overall 
antiproliferative effect of TKi and with the fact that c-MYC 
plays multiple roles, including the control of stem-cell clonal 
expansion, while NANOG and SOX2 are upregulated in asso-
ciation with the maintenance of cancer stem-cell pool [26, 
72]. The enhanced NANOG and SOX2 expression is also in 
keeping with the preferential effects of TKi on relatively 
less immature CML cell subsets, resulting in an apparent 
enrichment of stem-cell phenotype [11]. Finally, in a pre-
vious study of ours carried out with non-CML cells [70], 
NANOG was markedly down-regulated and c-MYC markedly 
upregulated upon G1-S transition. Our conclusion was that 
NANOG preserves slowly or non-cycling stem cells, while c-
MYC parallels stem-cell clonal expansion. In the same study, 
as far as KLF4 is concerned, changes of NANOG and KLF4 
expression appeared inversely proportional, their sum being 
constant across the different experimental variants, suggest-
ing that c-MYC expression (and thereby G1-S transition) be 
regulated by the NANOG/KLF4 ratio. Along this line, in 
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the present study, no statistically significant difference in 
expression levels of KLF4 was found between imatinib- and 
ponatinib-treated cells.
Additional interesting information came from CFA 
assays, which showed that, in both CML cell lines and 
patient-derived cells, ponatinib was, overall, more effective 
than imatinib in reducing progenitor/stem-cell potential. 
This effect was progressively reduced across subsequent 
replatings, in keeping with the notion that TKi get progres-
sively less effective as the hierarchical level of progenitor 
increases. This conclusion is further supported by the find-
ing that the progressive fading off of TKi effect was paral-
leled by the consistent effectiveness of XMD8-92, which we 
previously showed to exhibit an enhanced inhibitory action 
on the relatively more immature CML cells and on the main-
tenance of the CML stem cell compartment. Besides provid-
ing interesting pieces of evidence with respect to the effect 
of imatinib versus ponatinib, our experiments indicated that 
serial CFA assays are adequate to test the effects of drugs on 
leukemia progenitor/stem-cell subsets [8, 9, 12, 13, 38, 73].
Finally, the fact that the results obtained with primary 
cells were very similar to those obtained with stabilized 
CML cell lines suggests that the structure of the CML stem/
progenitor cell compartment within stabilized cell lines 
derived from patients in blast crisis is rather similar to that of 
primary cells explanted from patients in the chronic phase.
5  Conclusion
This study shows that ponatinib exhibited similar or supe-
rior effects to those of imatinib when tested on a panel of 
CML progenitor/stem-cell features. These in vitro results 
are well in keeping with the lower risk of relapse upon TKi 
discontinuation in patients treated with ponatinib [74]. How-
ever, in clinical practice, the superior effects of ponatinib 
over imatinib need to be balanced with the enhanced risk of 
adverse cardiovascular events consequent to ponatinib treat-
ment [75–77]. We addressed in detail elsewhere the ques-
tion of the phenotypical heterogeneity of the CML stem-cell 
compartment in terms of the sensitivity or resistance to TKi 
[78–80]. Nevertheless, this work provides a sizeable contri-
bution to the discussion of whether or not TKi are capable 
of targeting the CML stem-cell compartment. Finally, the 
experimental approach exploited here may be useful in the 
future for rapid and cost-effective preclinical screening of 
the capacity of treatments, including those with drugs that 
do not target BCR/ABL, to reduce or suppress cell subsets 
endowed with progenitor/stem-cell properties.
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